Chemicals & Small Molecules

Vantictumab (OMP-18R5), a fully human IgG2 monoclonal antibody, antagonizes Wnt pathway signaling through binding to FZD1/2/5/7/8 receptors. It is currently under investigation for the treatment of various cancers, including metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma [1] [2].

Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, facilitates the delivery of SN-38. It demonstrates anticancer activity [1].

Telisotuzumab vedotin (ABBV-399), an antibody-drug conjugate (ADCs), targets c-Met and comprises the cytotoxic agent Monomethyl Auristatin E (MMAE), the Telisotuzumab antibody, and a cleavable mc-val-cit-PABC linker. This compound is utilized in cancer research [1].

CVN636, a potent and selective allosteric agonist for the mGluR7 receptor, exhibits oral activity and CNS permeability [1], with an EC50 of 7 nM for human mGluR7.

NCGC00138783 TFA acts as a selective inhibitor of the CD47/SIRPα axis, exhibiting an inhibitory concentration (IC50) of 50 μM. This compound effectively obstructs the interaction between CD47 and SIRPα [1] [2].

MitoCur-1, a curcumin analogue, inhibits the mitochondrial antioxidative enzyme thioredoxin reductase 2 (TrxR2) and possesses electrophilic characteristics with mitochondrial-targeting capabilities. This compound specifically induces reactive oxygen species (ROS) generation, demonstrating antitumor efficacy [1].

Lemzoparlimab (TJ011133; TJC4), a humanized anti-CD47 IgG4 antibody, exhibits potent antitumor activity [1].

Anti-Mouse IL-1b Antibody is an IgG inhibitor specific to mouse IL-1b, derived from an Armenian Hamster host.

Atacicept (TACI-Ig), a recombinant fusion protein, comprises the extracellular, ligand-binding segment of the TACI receptor fused with the Fc portion of human IgG. It functions by inhibiting B cell activation through binding to both B lymphocyte stimulator and a proliferation-inducing ligand, and is utilized in researching B-cell autoimmune diseases [1] [2].